All Articles

Sunoco's acquisition of Offen Petroleum is more than a merger; it's a strategic consolidation reshaping the nation's energy backbone.

ESCO Technologies reports a stellar Q3 with 38% adjusted EPS growth and a record $1.5B backlog, proving its acquisition strategy is a powerful engine for growth.

The food-tech giant declared a routine dividend, but behind the curtain of record orders lies a significant asset writedown, raising questions about its health.

Starling Oncology just hit positive Adjusted EBITDA, a milestone for its value-based care model. Is this the inflection point for profitability in oncology?

As Turkey’s multi-billion dollar dental tourism market booms, one Istanbul clinic is challenging the 'package deal' model, betting on clinical integrity.

Notessa's appointment of a dual-expert in law and real estate signals a major shift in how AI will conquer complex industries—by focusing on people, not platforms.

Despite a dip in legacy revenue, Autoscope Technologies posts higher profits and doubles down on AI solutions aimed at making cities smarter and safer for all.

Karat Packaging's profits surged 168% thanks to a massive one-time tariff refund. A deep dive reveals the real story lies in its strategic growth.

With its Duchenne therapy nearing a pivotal FDA meeting, Solid Biosciences isn't just developing a drug; it's building a network for genetic repair.

After 15 years and 41 straight profitable quarters, PubMatic's CFO Steve Pantelick is retiring. A deep dive into his legacy and the ad tech firm's future.

Q2 results show growth, but rising costs and heavy spending underscore the pressure on Granite Ridge to hit its 2027 free cash flow inflection point.

APC's solid Q2 earnings are just half the story. A massive $235M acquisition in the Great Lakes signals a bold new phase of growth and consolidation.

A quiet revolution, mandated by the DoD, is dismantling the old guard of space acquisition. The move to modular systems is a strategic overhaul aimed at slashing costs, boosting innovation, and ensuring dominance in orbit.

With $911M in the bank, Relay Therapeutics is aggressively advancing its precision drug zovegalisib, targeting both breast cancer and rare vascular anomalies.

Beyond the mixed GAAP results, ICU Medical’s strong non-GAAP growth and raised guidance reveal a company thriving after a strategic pivot.

Sprout Social's stellar Q2 profit beat isn't just a good quarter; it's a strategic overhaul. A look at its high-stakes bet on enterprise clients and AI.

With 13% revenue growth and a massive buyback, CarGurus' Q2 results show its AI-first strategy is reshaping the auto market and rewarding investors.

While Q2 results show a net loss, Bridger Aerospace secures record contracts and expands its tech, signaling a strategic shift for a new era of wildfire.

iRhythm's stellar Q2 results are just the start. A major acquisition and a new AI algorithm are set to reshape the cardiac monitoring landscape.

With its lead obesity drug in late-stage trials and a Novo Nordisk veteran newly hired, Structure Therapeutics is making a calculated play for the oral GLP-1 crown.